FCA authorised · FRN 724952 0117 325 0027Quote & buy →
Life sciences consultants
Yes, pharmaceutical consultants need professional indemnity insurance, and it has to be a policy that actually covers life sciences work. Your submissions, GxP audits, batch certification and pharmacovigilance services sit inside your clients’ licences, so a mistake can delay an approval, fail an inspection or contribute to a recall. Those are financial losses that public liability will not pay. Many general PI wordings restrict pharmaceutical work, and clinical trials insurance and product liability are separate policies.
Part of: Professional indemnity for consultants
In short
Pharmaceutical consultants carry regulated responsibilities. Under the Human Medicines Regulations 2012, manufacturers need a qualified person (QP), wholesalers need a responsible person (RP), and marketing authorisation holders need a qualified person for pharmacovigilance (QPPV) based in the UK or EU. The MHRA can stop a failing QP or RP from acting. Serious suspected adverse reactions must be reported within 15 days. Since 28 April 2026 UK trials must follow ICH good clinical practice principles. PI covers negligent advice and services, but many wordings exclude life sciences work, product recall and fines. Product liability and clinical trials insurance are separate policies. GPhC registrants who practise as pharmacists must also have appropriate indemnity cover.
Last reviewed 5 October 2026 by the Apex professional indemnity team.
Public liability (PL) insurance covers accidental injury and damage, such as knocking over equipment during a site audit. Very little of a pharmaceutical consultant’s risk looks like that. You compile dossiers, audit manufacturing sites, write corrective action plans, certify batches, run pharmacovigilance systems and advise on what the MHRA will accept. Your work sits inside your clients’ licences and marketing authorisations, so an error tends to show up as a delayed approval, a critical inspection finding, a suspended licence or a recall.
Professional indemnity (PI) insurance covers your legal liability for financial loss caused by negligent advice or services, and the cost of defending the claim, subject to the policy terms. The catch for this trade is the wording. Many general PI policies exclude or restrict pharmaceutical, medical and life sciences work, clinical trials, or anything connected with a product that is ingested or administered. A consultancy policy bought for a different kind of business may simply not respond to your claims.
So the first question is not the price or the limit. It is whether the policy names the work you do, including any named regulatory roles you take on for clients, and whether any life sciences exclusion has been removed or rewritten.
The scenarios below are illustrative. They show the kind of allegation a pharmaceutical consultancy can face; they are not real claims or outcomes.
None of these involves an accident. Each alleges you did not show the skill and care expected of a competent regulatory, quality or pharmacovigilance professional.
Most of these duties fall on your client as licence or authorisation holder. When you perform them under contract, your work is judged against the same rules.
| Rule | What it requires | Where consultants come in |
|---|---|---|
| Human Medicines Regulations 2012, reg. 41 and Sch. 7 | A manufacturer’s licence holder must have at least one qualified person (QP) at its disposal at all times. The QP is responsible for securing that each batch has been manufactured and checked in line with the Regulations and the marketing authorisation. | Contract QP services and batch certification. |
| Human Medicines Regulations 2012, reg. 45 | A wholesale dealer’s licence holder must have a responsible person (RP) available at all times, with adequate knowledge and experience, to ensure licence conditions and product quality are maintained. | Contract RP and good distribution practice (GDP) support. |
| Human Medicines Regulations 2012, reg. 182 | A marketing authorisation holder must operate a pharmacovigilance system, with a qualified person responsible for pharmacovigilance (QPPV) who resides and operates in the UK or the EU, and a UK national contact person if the QPPV is outside the UK. | Outsourced pharmacovigilance and QPPV services. |
| Human Medicines Regulations 2012, reg. 188 | Serious suspected adverse reactions must be reported to the MHRA within 15 days of the holder learning of them, and non-serious UK reactions within 90 days. | Case processing and submission deadlines. |
| Marketing authorisation renewal (MHRA guidance) | A marketing authorisation is initially valid for five years, and holders should submit renewal applications nine months before it expires. | Regulatory affairs diaries and lifecycle management. |
| Good manufacturing and distribution practice (MHRA) | The MHRA inspects against GMP and GDP, grades deficiencies as critical, major or other, and may refer serious cases to its Inspection Action Group, which can refuse or suspend a licence. | Mock inspections, audits and remediation. |
| Medicines for Human Use (Clinical Trials) Regulations 2004, Sch. 1 | Since 28 April 2026, trials must follow the good clinical practice principles in the ICH guideline, and provision must be made for insurance or indemnity covering the liabilities of the investigator and sponsor. | GCP audits, and the reason trial insurance is the sponsor’s policy, not your PI. |
Many pharmaceutical consultants do more than advise. They are named as the QP on a manufacturer’s licence, the RP on a wholesale dealer’s licence or the QPPV for a portfolio of products. That changes the risk in three ways.
When you buy PI, tell the insurer which named roles you hold, for how many clients and for which product types. Ask whether the policy covers you as an individual as well as your company, how it treats costs of responding to a regulator, and whether claims involving recalls are excluded. PI is designed to answer a client’s civil claim against you, and PI wordings commonly exclude fines and penalties.
Three policies are regularly confused in life sciences, and a consultancy needs to know which one it is buying.
If you act as a sponsor’s representative, design protocols or manage trials, your PI may carry a clinical trials exclusion. Read it before you sign the contract, not after an incident.
| Usually covered by PI | Often excluded or limited | Needs a different policy |
|---|---|---|
| Negligent regulatory advice and submissions | Pharmaceutical and life sciences work, unless the wording affirms it | Injury caused by a medicine (the manufacturer’s or supplier’s product liability) |
| Errors in GMP, GDP and GCP audits and remediation plans | Product recall costs | Liabilities to trial participants (the sponsor’s clinical trials insurance) |
| Negligent performance of contract QP, RP or QPPV services, where declared | Fines, penalties and some regulatory costs | Claims against you as a director of a client company (directors’ and officers’ liability) |
| Pharmacovigilance case processing and reporting errors | Work for US clients or US submissions, unless agreed | Loss of safety data in a cyber attack (cyber insurance) |
| Defence costs, including regulatory expert evidence | Contractual warranties and liquidated damages | Injury to your own staff (employers’ liability) |
Every policy is different, and cover is always subject to the insurer’s acceptance and the policy terms. Quality and pharmacovigilance agreements often contain indemnities wider than negligence, so send them to your broker with the proposal.
The limit is usually set by your clients. Manufacturers, marketing authorisation holders and sponsors put PI requirements into consultancy, quality and pharmacovigilance agreements, and the figure tends to track what your work could cost them: the value of a product’s sales, a site’s output or a trial’s budget. A single recall or licence suspension can outweigh years of fees.
PI is claims-made. A batch certified this year can be questioned when a stability failure appears later, and a pharmacovigilance gap may only come to light at the next inspection, so the policy in force when the claim is made is the one that pays. If you retire, stop holding named roles or join a larger firm, arrange run-off. See run-off cover explained and aggregate and each and every claim limits.
A complete proposal gets better terms than a bare one, and a broker can only present what you tell us. Have these ready:
Speak to a broker
PI for pharmaceutical consultants, placed by a named broker
Start the online proposal and save it as you go, or leave your number and a named broker will call you back, usually the same working day.
Apex Insurance Brokers is an independent insurance broker based in Bristol, established in 2009 and authorised and regulated by the Financial Conduct Authority. We are not tied to one insurer: we work with over 30 markets, including Lloyd’s syndicates through wholesale brokers, and every client has a named broker who handles the placement, mid-term changes, certificates for clients and the renewal.
Yes. Your submissions, audits, batch certification and pharmacovigilance work can cost a client a delayed approval, a failed inspection or a recall, and those losses are financial. PI covers claims that your work was negligent, subject to the policy terms. Make sure the wording covers life sciences work, as many do not.
No law requires pharmaceutical consultants as such to hold PI. If you are a GPhC registrant practising as a pharmacist or pharmacy technician, the Pharmacy Order 2010 requires an indemnity arrangement giving appropriate cover for that practice. In practice manufacturers, marketing authorisation holders and sponsors also require PI in their contracts.
It can, if the policy names QP services and you have told the insurer which licences you are named on and what products they cover. A batch certification error can lead to a recall, so check whether recall costs are excluded and whether the policy covers you personally as well as your company.
No. Clinical trials insurance covers liabilities to trial participants, and the Clinical Trials Regulations require provision for insurance or indemnity covering the investigator’s and sponsor’s liabilities. That is normally the sponsor’s arrangement. Your PI covers negligent consultancy and may exclude clinical trials work altogether.
Usually, if pharmacovigilance is part of your declared business and any QPPV role is disclosed. Claims tend to involve late or missed adverse reaction reports, weak signal detection or gaps found at inspection. Serious cases must reach the MHRA within 15 days, so insurers will ask how you control case processing deadlines.
Usually not, if you supply services rather than products. Product liability is bought by the companies that make and supply medicines. If you import, label, distribute or otherwise handle products yourself, the position changes, and you should discuss product liability and your contracts with your broker.
Apex arranges professional indemnity insurance for pharmaceutical consultants across the UK. Tell us about your work and we’ll find cover that fits. Or call 0117 325 0027.
Start your PI proposal Call 0117 325 0027Apex Insurance Brokers Limited is authorised and regulated by the Financial Conduct Authority. Registered in England and Wales, company number 07014570. This page is general information, not advice on your individual circumstances. Cover is always subject to the insurer’s acceptance and the policy terms, and this page does not guarantee that cover will be available or on what terms.
